Monday, January 12, 2026

BMO Lowers Microsoft’s Price Target Due To US Dollar Strength

As earnings season is fast approaching, analysts are coming out with their previews, and one common theme amongst the previews is that large multi-national companies will see a material hit to their revenues due to the strength of the U.S Dollar.

The U.S dollar, measured by the U.S Dollar Currency Index DXY, is up 11% year to date and almost 16% from a year ago. The strength of the U.S dollar means in theory that multi-national companies who collect payments in native currencies will now be generating 15% less U.S dollar revenue than a year ago after converting all sales into USD.

With that in mind, Microsoft (Nasdaq: MSFT) was the first on the list as BMO Capital Markets lowered their fiscal fourth quarter and full year 2022/2023 estimates due to the strength of the U.S dollar. As a result, the company cut its 12-month price target from $345 to $305 and reiterated its outperform rating on the stock.

Microsoft currently has 52 analysts covering the stock with an average 12-month price target of $344.00. Out of the 52 analysts, 19 have strong buy ratings, 30 have buy ratings, and the last three analysts have hold ratings on the stock. The street high sits at $426, while the lowest is at $252.

In the note, BMO believes that even after the update Microsoft provided to the market on June 2, in which they pre-emptively cut their fourth-quarter guidance due to the rising dollar, that, “FX headwinds have increased in the past several weeks as the dollar has continued to strengthen.”

They say that if you average the changes to the pound, euro, and yen versus the U.S dollar, it equates to roughly an additional 3% depreciation. With this, they have lowered their revenue growth from 12.8% year over year to 12.6% to $51.959 million, which cuts their EPS estimate to $2.27 from $2.35. They now expect cash flow per share to be $2.46, slightly down from $2.49.

BMO has also taken the time to lower its full-year 2023 estimates. They previously had revenues coming in at $227.194 million. Now they expect revenues to come in at $222.318 million, which is a roughly 12% increase year over year. They now expect earnings per share to be $10.40 and cash flow per share to be $9.86 for the fiscal full year 2023.

Lastly, BMO introduced their fiscal full year 2024 estimate, in which they believe that the current strength of the U.S dollar won’t be an issue. Below you can see their 2024 guidance.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why Silver Needs to Slow Down to Go Higher | Dan Dickson – Endeavour Silver

Silver Dips Are Getting Bought, This Is How Breakouts Start | John Feneck

Why $100 Silver Right Now Would Be a Problem | Keith Neumeyer – First Majestic

Recommended

Antimony Resources Drills 8.48% Sb Over 3 Metres, 2.07% Sb Over 27 Metres At Bald Hill

Steadright To Acquire 75% Interest In Moroccan Copper-Lead-Silver Project

Related News

Hexo: Canaccord Cuts Price Target In Half To $1.00

On December 14th, Hexo Corp (TSX: HEXO) reported its fiscal first quarter 2022 results. The...

Saturday, December 18, 2021, 01:23:00 PM

Karora: Haywood Reiterates Ratings After Three Year Guidance Announcement

On June 28th, Karora Resources Inc. (TSX: KRR) announced its three-year production guidance, whereby they...

Wednesday, June 30, 2021, 04:53:00 PM

Canopy Growth: Analysts Anticipate Q1 Revenues Of $149 Million

Canopy Growth Corp (TSX: WEED) (NASDAQ: CGC) announced that they will be reporting their fiscal...

Tuesday, August 3, 2021, 03:28:00 PM

Raymond James Reiterates $6 Price Target On Organigram Holdings

On April 6th, Organigram Holdings (TSX: OGI) (NASDAQ: OGI) announced that they acquired cannabis 2.0...

Thursday, April 8, 2021, 10:37:00 AM

Well Health: Canaccord Reiterates Ratings Following Recent Acquisition

Last week WELL Health Technologies (TSX: WELL) announced their latest acquisition, a majority stake in...

Friday, September 10, 2021, 03:29:00 PM